Cardio-oncology最新文献

{"title":"Diagnostic and prognostic biomarkers in heart failure and myeloproliferative neoplasms: clinical applications and risk scores - a narrative review.","authors":"Ionela-Raluca Muraretu, Adriana Luminita Gurghean, Adrian Gradinaru, Mircea Bajdechi, Ilinca Savulescu-Fiedler, Anca-Maria Mihailescu, Adriana Mihaela Iliesiu","doi":"10.1186/s40959-026-00518-7","DOIUrl":"10.1186/s40959-026-00518-7","url":null,"abstract":"<p><p>Heart failure (HF) remains a leading cause of morbidity and mortality worldwide and frequently coexists with Philadelphia-negative myeloproliferative neoplasms (MPNs), which share thrombo-inflammatory pathways that increase cardiovascular risk. HF is often underestimated in this population, and current risk models rarely include variables specific to this complex cardio-hematologic setting. From a cardio-oncology perspective, MPNs represent a prototypical at-risk cancer population in whom chronic inflammation, clonal hematopoiesis, and cancer therapy converge to accelerate cardiovascular damage.This narrative review summarizes current evidence on diagnostic and prognostic biomarkers, imaging parameters, and validated HF and MPNs risk scores, and proposes a pragmatic hybrid framework for integrated HF-MPNs cardiovascular risk assessment. PubMed, Embase, and Web of Science were searched up to December 2025 using combinations of terms related to HF, MPNs, biomarkers, imaging, and risk models. In HF, natriuretic peptides and cardiac troponins remain central for diagnosis and short-term prognosis, whereas emerging biomarkers such as galectin-3, soluble ST2, and GDF-15 refine long-term risk prediction. Advanced imaging tools, including global longitudinal strain, left atrial strain, and cardiac magnetic resonance tissue characterization, provide prognostic value beyond the left ventricular ejection fraction. Multidimensional HF models (e.g., MAGGIC, SHFM, BCN Bio-HF, H2FPEF, 3A3B, GWTG-HF, ADHERE, and EHMRG) combine different variables to estimate mortality and hospitalization risk. In MPNs, blood counts, driver mutations (JAK2, CALR, MPL), inflammatory markers, and scores such as IPSET-thrombosis, DIPSS/DIPSS-plus, and MIPSS stratify thrombotic risk, survival, and leukemic transformation but seldom incorporate HF-specific variables.No single biomarker or score fully captures the bidirectional cardiovascular risk in patients with HF and coexisting MPNs. We propose a simple 0-8-point composite algorithm that combines key HF and MPNs variables (natriuretic peptides or troponins, HF risk scores, driver mutations, leukocytosis/thrombocytosis, LDH) to identify high-risk HF-MPNs phenotypes across ACC/AHA HF Stages A-C, suitable for structured cardio-oncology follow-up. Prospective validation of this hybrid algorithm in dedicated cardio-oncology cohorts and the development of MPNs-adapted HF guidelines are key future priorities.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13422315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148194664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A smartphone application for cardiovascular rehabilitation in cancer survivors.","authors":"Mohadeseh Sadat Khorashadizadeh, Haleh Ayatollahi, Marjan HajAhmadi Pour Rafsanjani","doi":"10.1186/s40959-026-00514-x","DOIUrl":"10.1186/s40959-026-00514-x","url":null,"abstract":"<p><strong>Background: </strong>Cancer is a leading cause of morbidity and mortality worldwide, with millions of survivors facing long-term health complications, particularly cardiovascular diseases (CVD). Treatments such as chemotherapy and radiation therapy can induce cardiotoxicity, resulting in significant cardiovascular morbidity. As cancer survival rates improve, the need for effective management strategies to address the cardiovascular health of cancer survivors has become increasingly critical. This study aimed to develop a smartphone-based application for cardiovascular rehabilitation in cancer survivors.</p><p><strong>Methods: </strong>This research was conducted in two phases. In the first phase, users' requirements were investigated by using a questionnaire. The participants were 31 cardio-oncologists. In the second phase, a prototype of the application was designed and implemented, and its usability was evaluated quantitatively by 27 cancer survivors with cardiovascular complications and eight cardio-oncologists using a QUIS questionnaire (version 5.5). The statistical analysis was conducted using SPSS software, version 28.</p><p><strong>Results: </strong>Most of the proposed educational content, data elements, and application features, including necessary steps to prevent cardiovascular complications in cancer survivors, risk factors for cardiovascular complications in cancer survivors, guidance on quitting smoking and exercise training, the ability to track personal and clinical data, fatigue and anxiety assessments, and communication with physicians, were considered essential items for the application. Ultimately, users evaluated the application's usability, resulting in an average mean score of 8.19 out of 9 from patients' perspectives and 8.22 out of 9 from cardio-oncologists, indicating a \"good\" level of user satisfaction.</p><p><strong>Conclusion: </strong>The development of a smartphone-based application for cardiovascular rehabilitation in cancer survivors represents a significant step toward improving cardiovascular health management in this vulnerable population. However, more research is needed to compare the effects of remote education versus face-to-face rehabilitation on improving health literacy and patient exercise adherence.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13465133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148155558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addition of malignancy into the CHADS2/CHA2DS2VASc score: better prediction of stroke risk in individuals with cancer and atrial fibrillation.","authors":"Zoha Majeed, Rochell Issa, Tess Calcagno, Ryan Issa, Neehal Shukla, Rohan Prasad, Arianne Clare Agdamag, David C Kaelber, Diego Sadler, Alok A Khorana, Mohamed Kanj, Rohit Moudgil","doi":"10.1186/s40959-026-00513-y","DOIUrl":"10.1186/s40959-026-00513-y","url":null,"abstract":"<p><strong>Purpose: </strong>The CHADS₂ and CHA₂DS₂VASc scoring systems guide thromboprophylaxis in atrial fibrillation (AF), but their performance is limited in patients with cancer. This study evaluated whether malignancy functions as an independent risk factor for ischemic stroke among patients with AF.</p><p><strong>Methods: </strong>Using the TriNetX research network, we identified patients with AF with and without malignancy between 2015 and 2022, excluding those with prior cerebrovascular disease. Propensity score matching for CHA₂DS₂VASc variables and anticoagulation yielded two cohorts of 234,428 patients each. The primary outcome was ischemic stroke; secondary outcomes included major bleeding and all-cause mortality. Outcomes were assessed at 3 months, 6 months, 1 year, and 5 years following the index event.</p><p><strong>Results: </strong>At 3 months, stroke incidence was significantly higher among patients with AF and malignancy compared with AF alone (OR 2.092; CI 1.990-2.200). This increased risk persisted at 6 months (OR 1.978), 1 year (OR 1.795), and 5 years (OR 1.585). Mortality and major bleeding rates were also consistently higher in the AF and malignancy cohort across all time intervals.</p><p><strong>Conclusion: </strong>Patients with AF and malignancy demonstrated a significantly higher risk of ischemic stroke despite matching for established CHA₂DS₂VASc risk factors, supporting malignancy as a potential independent contributor to stroke risk. Mortality and major bleeding were likewise higher, reflecting the combined burden of malignancy and AF. The relative odds of ischemic stroke exceeded those of major bleeding across all time points. Future studies should evaluate whether incorporating malignancy into the CHA₂DS₂VASc score improves stroke risk stratification in this population.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13463736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148155496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between extreme temperatures and hospitalizations among Chinese cancer patients with atrial fibrillation: a case-crossover study.","authors":"Shihao Wang, Yuhang Wen, Shaobo Shi, Xiaolei Yang, Congxin Huang, He Huang, Yunlong Xia","doi":"10.1186/s40959-026-00519-6","DOIUrl":"10.1186/s40959-026-00519-6","url":null,"abstract":"<p><strong>Background: </strong>Temperature extremes are established triggers of cardiovascular events in the general population, while cancer patients face elevated atrial fibrillation (AF) risk due to disease- and treatment-related factors. However, whether cancer confers additional vulnerability to temperature-related AF events remains unclear. This study aimed to examine the association between extreme temperatures and AF hospitalizations in cancer patients compared with non-cancer controls.</p><p><strong>Methods: </strong>Data were derived from the real-world study of the Chinese AF registry (2014-2023), comprising 1,665,014 AF hospitalizations. This study is an exploratory, cancer-focused secondary analysis of the RWS-CAF registry. Overall associations between ambient temperature and AF hospitalization in the full registry have been reported separately. We used a time-stratified case-crossover design with distributed lag nonlinear models to assess temperature-AF associations. Cancer patients (n = 243482) were compared with demographically matched non-cancer controls, and unmatched analyses were performed in the full cohort. Subgroup analyses examined effect modification by age, sex, and geographic region.</p><p><strong>Results: </strong>Extreme cold (1st percentile, - 5.6 °C) was associated with higher AF hospitalization risk in cancer patients (RR 1.80, 95% CI 1.60-2.03) compared with matched non-cancer controls (RR 1.27, 95% CI 1.21-1.34; P_interaction < 0.001). The nonoptimal temperature-attributable fraction was also higher in the cancer group (19.7%) than in matched non-cancer patients (10.2%), with cold exposure accounting for the majority of the burden. Among cancer patients, the cold-related RR was higher in males (1.86, 1.62-2.15) than in females (1.37, 1.26-1.50; P_interaction < 0.001), and the cold-related RR was higher in northern than in southern China (P_interaction = 0.002). Lag-specific analyses suggested earlier onset and more persistent cold-related risk elevation in the cancer group.</p><p><strong>Conclusions: </strong>Patients with cancer appeared more vulnerable to cold-related AF hospitalization than those without cancer, with stronger associations observed in men and in northern regions. These findings support the possibility that cancer modifies the temperature-AF relationship and warrant confirmation in studies with prespecified analyses and more detailed oncologic characterization.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13466510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148155483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Midodrine to facilitate cardioprotective therapy in hypotensive HER2-positive breast cancer patients with cancer-therapy-related cardiac dysfunction-multicenter case experience.","authors":"Efstratios Koutroumpakis, Cezar Iliescu, Anita Deswal, Charles Porter","doi":"10.1186/s40959-026-00504-z","DOIUrl":"10.1186/s40959-026-00504-z","url":null,"abstract":"<p><strong>Background: </strong>HER2-targeted therapies significantly improve outcomes in HER2-positive breast cancer but are associated with cancer therapy-related cardiac dysfunction (CTRCD), which may necessitate interruption of oncologic treatment. Hypotension, which is not uncommon in patients with cancer, may limit the use of guideline-directed medical therapy (GDMT) required for left ventricular (LV) recovery, and no approved strategy exists to safely augment blood pressure in this setting.</p><p><strong>Case presentation: </strong>We report two cases of hypotensive breast cancer patients who developed CTRCD during HER2-targeted therapy and were unable to tolerate GDMT due to symptomatic hypotension. In both cases, initiation and titration of midodrine enabled stabilization of blood pressure, facilitation of cardioprotective therapy with beta-blockers and/or sodium-glucose cotransporter-2 inhibitors, and subsequent recovery of LV systolic function. This strategy allowed continuation or reinitiation of life-prolonging HER2-directed therapy without worsening heart failure or significant adverse effects.</p><p><strong>Discussion and conclusions: </strong>Midodrine may serve as a practical hemodynamic adjunct to enable guideline-directed cardioprotective therapy in selected hypotensive patients with HER2 therapy-related cardiomyopathy. These cases illustrate the feasibility of blood pressure augmentation as a strategy to facilitate cardiac recovery while preserving access to essential oncologic therapy. They do not establish efficacy or safety, and prospective studies with systematic assessment and predefined endpoints are warranted to define patient selection and long-term outcomes.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13425978/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148052958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted autonomic testing for radiation‑induced baroreflex failure in head and neck cancer survivors: index case and early program experience.","authors":"Efthymios Triantafyllou, Ingrid González Flores, Cezar Iliescu, Anita Deswal, Elie Mouhayar, Clifton D Fuller, Efstratios Koutroumpakis","doi":"10.1186/s40959-026-00501-2","DOIUrl":"10.1186/s40959-026-00501-2","url":null,"abstract":"<p><p>Radiation‑induced afferent baroreflex failure (R‑ABF) is a highly morbid late effect of neck irradiation in head and neck cancer survivors, and is frequently underrecognized due to nonspecific, fluctuating symptoms. We report an index case in which systematic autonomic evaluation-including adrenergic and cardiovagal assessment-enabled objective diagnosis, severity grading, while physiology‑directed therapy resulted in meaningful symptomatic improvement. The diagnostic trajectory highlights recurrent challenges: prolonged latency from symptom onset to recognition, therapeutic complexity in the setting of cardiovascular comorbidities, and limited access to standardized autonomic testing. In response, we have developed the BARO‑CARE Program, a structured pathway integrating comprehensive autonomic profiling to streamline diagnosis, guide individualized management, and support longitudinal monitoring. This case and early program experience emphasize that even chronic R‑ABF remains therapeutically modifiable when approached with pathophysiologically‑guided care. Programmatic, multidisciplinary models may reduce diagnostic delays and improve outcomes as the survivor population grows.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":"12 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13220401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148052989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hidden hazards in the cath lab: cancer morbidity among interventional cardiologists.","authors":"Nasser G Alqahtani","doi":"10.1186/s40959-026-00489-9","DOIUrl":"10.1186/s40959-026-00489-9","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to summarize the existing evidence regarding the cancer prevalence and its types in interventional cardiologists (ICs).</p><p><strong>Methods: </strong>A systematic literature search was conducted from inception till July 13, 2025.</p><p><strong>Results: </strong>Across the six cross-sectional studies (n = 1,893 ICs), 77 ICs (4.1%) reported cancer morbidity, with prevalence estimates ranging from 2% to 6%. More than 40% of ICs had occupational radiation exposure for over 15 years. Cancer types were specified in 24 ICs, with breast cancer (33.3%) and brain tumors (33.3%) being the most frequently reported, followed by skin cancer (20.8%), leukemia (8.3%), and head and neck cancer (4.2%).</p><p><strong>Conclusion: </strong>While causality cannot be established, these findings underscore the importance ofenhanced radiation protection strategies, systematic health surveillance, and the needfor large prospective studies to better define cancer risk in this population.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":"12 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13220626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148052986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement.","authors":"Susan Dent, Michelle B Nadler, Anne Blaes, Ahamed Iqbal, Hannah Naa Gogwe Ayettey, Jose Alvarez-Cardona, Alexandre Chan, Eng-Siew Koh, Raul Cordoba Mascunano, Mridula George, Naa Adorkor Aryeetey, Erin J Howden, Sase Kazuhiro, Nida Latif, Aya F Ozaki, Cherith J Semple, Sivatharshini Ramalingam, Neil M Iyenger, Hope S Rugo, Bogda Koczwara","doi":"10.1186/s40959-026-00481-3","DOIUrl":"10.1186/s40959-026-00481-3","url":null,"abstract":"<p><strong>Purpose: </strong>Cardiovascular (CV) toxicity is prevalent in cancer survivors due to shared risk factors, direct CV injury from cancer therapy (CT), and development/exacerbation of CV risk factors during treatment. Succinct guidance on the minimum standard of CV care required of cancer care providers (CCPs) can improve outcomes for survivors. This clinical practice statement (CPS) is aimed at CCPs focused on identification, prevention, and management of CVD in individuals with cancer.</p><p><strong>Methods: </strong>The International Cardio-Oncology Society and Multinational Association of Supportive Care in Cancer identified members with expertise across oncology, cardiology, and cancer survivorship. Key questions/areas of practice recommendations related to CV risk and CVD were identified across the cancer trajectory.Working groups performed targeted literature reviews and consensus was reached for all recommendations.</p><p><strong>Results: </strong>5 over-arching clinical practice recommendations for CCPs were identified: (1) perform a CV risk assessment prior to starting systemic CT (2) identify and facilitate CV-related care during CT; (3) ensure measures are taken to mitigate the risk of cancer therapy related CV toxicity (CTR-CVT) prior to and during CT; (4) monitor CV status and risk factors during therapy and refer to the appropriate health care provider if CV risk factors are uncontrolled or new signs/symptoms develop; and (5) re-assess CV risk following completion of CT (periodically for those with advanced disease on life long treatment) and develop a CV surveillance plan.</p><p><strong>Conclusions: </strong>CCPs play a pivotal role in identifying and addressing CTR-CVT. This CPS provides specific, succinct, and actionable behaviours that can be readily implemented in cancer care globally.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":"12 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13220357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148052963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling temporal trends and disparities in mortality with co-listed coronary artery disease and cancer, 1999-2024: insights from the CDC WONDER multiple cause of death database.","authors":"Saifullah Khan, Muhammad Hussain, Muhammad Hassan, Nisha Khalid, Javeria Nawaz, Maria Baig, Fnu Pirih, Ahmad Anees Qureshi, Zona Shaikh, Sherif Eltawansy, Stephen J Greene, Gregg C Fonarow, Marat Fudim, Saad Ahmed Waqas, Asma Naz, Hasibullah Aminpoor","doi":"10.1186/s40959-026-00517-8","DOIUrl":"10.1186/s40959-026-00517-8","url":null,"abstract":"<p><strong>Background: </strong>Coronary artery disease (CAD) remains one of the primary causes of morbidity and mortality worldwide. Although cancer mortality rates have declined in many high-income countries, including the United States, substantial variability persists. This study aimed to assess the trends and disparities in mortality among adults with co-listed CAD and cancer on death certificates.</p><p><strong>Methods: </strong>We conducted a retrospective analysis using the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) Multiple Cause-of-Death database. Data were extracted for co-listed CAD and cancer spanning from 1999 to 2024. Age adjusted mortality rates (AAMRs) were calculated. The Joinpoint Regression Program was used to evaluate annual percentage changes (APC) and average annual percentage change (AAPC) with 95% confidence intervals (CI).</p><p><strong>Results: </strong>Over 26 years, 1,321,891 deaths occurred with co-listed CAD and cancer. The overall AAMR decreased from 31.38 in 1999 to 19.77 in 2024 (AAPC: -1.88, 95% CI: -2.01 to -1.77). Men had higher mean AAMRs (36.86) than women (13.93). Among races, the highest mean AAMRs were observed in Non-Hispanic (NH) White (23.84), and NH Black (22.1), followed by NH American Indian or Alaskan Native (15.28), Hispanic (14.00), and NH Asian or Pacific Islander (11.44) individuals. Regionally, the Midwest showed higher mean AAMR (25.21), then Northeast (24.88), South (21.93), and West (21.33). Age group categorization showed highest mean AAMR in older adults (107.05), followed by middle-aged adults (6.35), and younger adults (0.18). Stratified by urbanization, rural areas exhibited higher mean AAMR (27.58) compared to urban areas (22.92). Among states, the highest mortality rates were observed in West Virginia (35.86).</p><p><strong>Conclusion: </strong>The AAMR for co-listed CAD and cancer has decreased from 1999 to 2024, with significant disparities persisting in demographics and different regions. These disparities highlight the need for targeted, equitable public health interventions to reduce mortality in these vulnerable populations.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13411586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148052930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardio-Oncology Nursing Education (CONE): an innovative educational program for nurses caring for patients with cancer and concurrent cardiovascular disease.","authors":"Anecita Fadol, Lisa Nodzon, Priya Reehal, Asma Mouhammad Younus, Chelsea Patricia Kriesberg, Mary Stuart, Edith Pituskin, Geraldine Lee","doi":"10.1186/s40959-026-00516-9","DOIUrl":"10.1186/s40959-026-00516-9","url":null,"abstract":"<p><strong>Background: </strong>Cardio-oncology addresses the cardiovascular health of patients with cancer, an area of growing importance as cancer survival rates improve. Nurses play a central role in monitoring, educating, and coordinating care, yet a structured, standardized, competency-based education is lacking. This article describes the development, structure, and implementation of the Cardio-Oncology Nursing Education (CONE) program, a global educational initiative designed to equip nurses with specialized knowledge and skills to manage cardiovascular complications in patients with cancer.</p><p><strong>Methods: </strong>The CONE curriculum was developed by an international, multidisciplinary committee, informed by a global nursing learning-needs assessment. It comprises 27 virtual modules, providing 18.25 nursing contact hours, including 10.25 pharmacotherapeutics credits accredited by the American Nurses Credentialing Center, aligned with contemporary evidence-based guidelines. Modules cover cardiovascular risk assessment, therapy-related toxicity, survivorship, and multidisciplinary care coordination.</p><p><strong>Conclusions: </strong>The CONE program provides a standardized, evidence-based framework for cardio-oncology nursing education, promoting nurse-led, patient-centered care and improving outcomes for cancer survivors. The asynchronous, flexible curriculum addresses global accessibility barriers and supports learner-directed professional development. Future directions include hybrid learning, simulation-based education, and competency-based certification to formalize nursing roles globally.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13411328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148027654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}